Pacific Edge Limited (PFGTF) has released an update.
Chris Gallaher, Chairman of Pacific Edge Limited, a leading cancer diagnostics company, has postponed his retirement to continue leading the firm into 2025 amidst ongoing uncertainty with Medicare coverage for their Cxbladder tests and the search for his successor. The delay comes as the company awaits a final decision on the Local Coverage Determination from Novitas, which affects the U.S. lab’s operations. This move aims to ensure a smooth transition and maintain stability for the stakeholders of the New Zealand-based company specializing in bladder cancer diagnostics.
For further insights into PFGTF stock, check out TipRanks’ Stock Analysis page.
